BioHarvest Sciences (NASDAQ:BHST) Posts Earnings Results, Meets Estimates

BioHarvest Sciences (NASDAQ:BHST) released its quarterly earnings data on Thursday. The company reported ($0.11) EPS for the quarter, hitting analysts’ consensus estimates of ($0.11), Zacks reports. The company had revenue of $8.51 million during the quarter, compared to the consensus estimate of $8.50 million. BioHarvest Sciences had a negative net margin of 32.27% and a negative return on equity of 136.42%.

Here are the key takeaways from BioHarvest Sciences’ conference call:

• BioHarvest reported Q1 2026 revenue of $8.5 million, up 8% year over year, with gross margin holding near 59%. Net loss was $2.6 million and adjusted EBITDA loss was $1.2 million, roughly in line with last year.
• The company highlighted major progress in its CDMO pipeline, including completion of stage 1 for both a rare fragrance ingredient and SaffronTech’s saffron program, and the signing of a $1.2 million stage 2 fragrance contract.
• Management said the fragrance program has meaningful long-term upside, with BioHarvest retaining 20% ownership of the developed compositions and expecting commercialization to begin in the second half of 2027. They also reiterated a 2026 CDMO revenue guide of $12 million to $14 million.
• In the D2C business, Q1 was described as a “reset quarter” as the company reduced and reworked marketing spend, which weighed on near-term growth. Management said the full benefits of the new approach should show up more meaningfully in the second half of the year.
• VINIA Blood Flow Hydration showed strong early traction, with management citing high customer ratings, growing sales on Amazon and TikTok, and rising seasonality benefits ahead. The company kept full-year D2C revenue guidance at $38 million to $42 million and said it remains focused on improving LTV/CAC efficiency.

BioHarvest Sciences Price Performance

BHST stock traded down $0.00 during midday trading on Friday, reaching $4.16. 3,206 shares of the company’s stock traded hands, compared to its average volume of 29,781. The company has a 50-day simple moving average of $4.26 and a two-hundred day simple moving average of $5.30. The company has a quick ratio of 3.38, a current ratio of 3.97 and a debt-to-equity ratio of 0.10. BioHarvest Sciences has a 1-year low of $3.57 and a 1-year high of $12.80. The company has a market cap of $81.60 million, a price-to-earnings ratio of -6.82 and a beta of 0.81.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on BHST. Roth Mkm started coverage on BioHarvest Sciences in a report on Thursday, February 19th. They issued a “buy” rating and a $10.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioHarvest Sciences in a research note on Friday, March 27th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $10.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC bought a new position in shares of BioHarvest Sciences in the fourth quarter worth about $60,000. Geode Capital Management LLC bought a new position in BioHarvest Sciences in the 4th quarter worth approximately $61,000. HRT Financial LP acquired a new position in BioHarvest Sciences during the 4th quarter worth $75,000. Marshall Wace LLP acquired a new position in BioHarvest Sciences during the 4th quarter worth $110,000. Finally, Quadrature Capital Ltd bought a new position in BioHarvest Sciences in the 4th quarter valued at $140,000.

Key BioHarvest Sciences News

Here are the key news stories impacting BioHarvest Sciences this week:

• Positive Sentiment: Q1 revenue rose 8% year over year to $8.51 million, slightly ahead of expectations, while adjusted results matched consensus and the loss per share was better than feared. BioHarvest Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Management said CDMO revenue grew 135% year over year and highlighted milestones in its fragrance and saffron projects, suggesting momentum in higher-growth initiatives. BioHarvest Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: The company reiterated full-year 2026 revenue guidance of $42 million to $48 million, and separately outlined 2026 expectations of $38 million to $42 million in direct-to-consumer sales plus $12 million to $14 million in CDMO activity. BioHarvest outlines 2026 revenue of $38M-$42M in D2C and $12M-$14M in CDMO activity while targeting 2H 2027 fragrance production
• Positive Sentiment: VINIA’s customer base reached 90,000 active users by the end of April, indicating continued growth in the company’s direct-to-consumer business. BioHarvest Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
• Neutral Sentiment: BioHarvest filed its Q1 2026 financials on Form 6-K and held its earnings call, which confirms the reported results but is not a major new catalyst on its own. BioHarvest Sciences Files Q1 2026 Financials on Form 6-K
• Negative Sentiment: The company remains unprofitable, posting a $0.11 per-share loss, with negative net margin and return on equity, which may limit upside until earnings improve. Listen to Conference Call

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.